CL2021001018A1 - Formulación basada en ciclodextrina de un inhibidor de bcl-2 - Google Patents

Formulación basada en ciclodextrina de un inhibidor de bcl-2

Info

Publication number
CL2021001018A1
CL2021001018A1 CL2021001018A CL2021001018A CL2021001018A1 CL 2021001018 A1 CL2021001018 A1 CL 2021001018A1 CL 2021001018 A CL2021001018 A CL 2021001018A CL 2021001018 A CL2021001018 A CL 2021001018A CL 2021001018 A1 CL2021001018 A1 CL 2021001018A1
Authority
CL
Chile
Prior art keywords
cyclodextrin
pharmaceutical composition
relates
bcl
inhibitor
Prior art date
Application number
CL2021001018A
Other languages
English (en)
Inventor
Maïa Chanrion
Jean-Manuel Pean
Caroline Chemin
Thu Thuy Tran
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Publication of CL2021001018A1 publication Critical patent/CL2021001018A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a una composición farmacéutica que comprende 5-(5-cloro-2-{[(3S)-3- (morfolin-4-ilmetil)-3,4-dihidroisoquinolin-2(1H)-il]carbonil}fenil)-N-(5-ciano-1,2-dimetil- 1H-pirrol-3-il)-N-(4-hidroxifenil)-1,2-dimetil-1H-pirrol-3-carboxamida, referida en la presente memoria como ‘Compuesto A’, o una sal farmacéuticamente aceptable de la misma, y una ciclodextrina. Más específicamente, la invención se refiere a una composición farmacéutica sólida que comprende el Compuesto A y una ciclodextrina, y una composición farmacéutica para administración parenteral preparada disolviendo esta composición farmacéutica sólida. Además, la invención se refiere al uso de dichas composiciones para el tratamiento del cáncer.
CL2021001018A 2018-10-31 2021-04-21 Formulación basada en ciclodextrina de un inhibidor de bcl-2 CL2021001018A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862753164P 2018-10-31 2018-10-31

Publications (1)

Publication Number Publication Date
CL2021001018A1 true CL2021001018A1 (es) 2021-11-26

Family

ID=68536777

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001018A CL2021001018A1 (es) 2018-10-31 2021-04-21 Formulación basada en ciclodextrina de un inhibidor de bcl-2

Country Status (25)

Country Link
US (1) US20210353633A1 (es)
EP (1) EP3873529A1 (es)
JP (1) JP2022506069A (es)
KR (1) KR20210102886A (es)
CN (1) CN112912108A (es)
AR (1) AR116922A1 (es)
AU (1) AU2019373373B2 (es)
BR (1) BR112021007987A2 (es)
CA (1) CA3117511A1 (es)
CL (1) CL2021001018A1 (es)
CO (1) CO2021005221A2 (es)
CR (1) CR20210210A (es)
DO (1) DOP2021000073A (es)
EA (1) EA202191144A1 (es)
GE (1) GEP20237580B (es)
IL (1) IL282688A (es)
JO (1) JOP20210079A1 (es)
MX (1) MX2021004864A (es)
NI (1) NI202100031A (es)
PE (1) PE20211738A1 (es)
PH (1) PH12021550878A1 (es)
SG (1) SG11202103965TA (es)
TW (1) TWI738100B (es)
UY (1) UY38431A (es)
WO (1) WO2020089286A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023001335A (es) 2020-07-31 2023-04-27 Servier Lab Combinacion de un inhibidor de bcl-2 y un agente hipometilante para tratar canceres, usos y composiciones farmaceuticas de la misma.
WO2022090443A1 (en) 2020-10-30 2022-05-05 Les Laboratoires Servier Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
JP2024511422A (ja) 2021-03-24 2024-03-13 レ ラボラトワール セルヴィエ ５－｛５－クロロ－２－［（３ｓ）－３－［（モルホリン－４－イル）メチル］－３，４－ジヒドロイソキノリン－２（１ｈ）－カルボニル］フェニル｝－１，２－ジメチル－１ｈ－ピロール－３－カルボン酸誘導体を合成するための新規な製造方法及び医薬化合物を製造するためのその適用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041646A2 (en) * 1995-06-13 1996-12-27 Dyer, Alison, Margaret Pharmaceutical compositions containing lornoxicam and cyclodextrin
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
WO2014108918A2 (en) * 2013-01-08 2014-07-17 Mylan Laboratories Limited An injectable antifungal formulation
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2018081830A1 (en) * 2016-10-31 2018-05-03 Oregon Health & Science University Combinations of agents to treat hematological malignancies

Also Published As

Publication number Publication date
TW202031295A (zh) 2020-09-01
CO2021005221A2 (es) 2021-07-19
SG11202103965TA (en) 2021-05-28
UY38431A (es) 2020-05-29
TWI738100B (zh) 2021-09-01
IL282688A (en) 2021-06-30
GEP20237580B (en) 2023-12-25
CN112912108A (zh) 2021-06-04
DOP2021000073A (es) 2021-11-15
AR116922A1 (es) 2021-06-30
KR20210102886A (ko) 2021-08-20
MX2021004864A (es) 2021-08-11
EP3873529A1 (en) 2021-09-08
AU2019373373A1 (en) 2021-05-20
EA202191144A1 (ru) 2021-09-27
PE20211738A1 (es) 2021-09-06
US20210353633A1 (en) 2021-11-18
BR112021007987A2 (pt) 2021-08-03
NI202100031A (es) 2021-08-24
JOP20210079A1 (ar) 2023-01-30
CA3117511A1 (en) 2020-05-07
AU2019373373B2 (en) 2023-09-28
JP2022506069A (ja) 2022-01-17
PH12021550878A1 (en) 2021-10-18
CR20210210A (es) 2021-05-25
WO2020089286A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
CL2021001018A1 (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
BR112016011949A2 (pt) Composto, composição farmacêutica, e, uso dos mesmos”
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
AR051099A1 (es) Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
HUP0303271A2 (hu) Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására
ECSP088240A (es) Composición de trazodona para administración una vez por día
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
CO6280574A2 (es) Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia
CL2021001629A1 (es) Compuestos de halo-alilamina y uso de los mismos
WO2012168885A9 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
US20150231198A1 (en) Combination therapy for hematological malignancies
BR112022002392A2 (pt) Formas em estado sólido de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetra-hidronaftalen-2-il)amino)-n-(1-(2-metil-1)-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida e seus usos
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
RU2006127422A (ru) Антимикробные консерванты для достижения мультидозовых рецептур с использованием бета-циклодекстринов для жидких лекарственных форм
JP2018506533A5 (es)
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
SV2011004017A (es) Tratamiento del cancer de pancreas
BRPI0418743A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
BR112022019864A2 (pt) Composto de oxofenilarsina deuterada e uso do mesmo